Disease × agent evidence record

Low-Dose Naltrexone (LDN) for ME/CFS: evidence, trials and status

Trials of Low-Dose Naltrexone (LDN) in ME/CFS are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest.

2registered trials
1recruiting
8publications
BEvidence tier · Moderate
29.0Score
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Low-Dose Naltrexone (LDN) is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 2 registered trials linking Low-Dose Naltrexone (LDN) to ME/CFS: 1 is currently recruiting; 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT06366724, sponsored by Brigham and Women's Hospital). It plans or enrolled 160 participants. Registration activity spans 2024 to 2026. The literature layer holds 8 publications for this pair: 8 curated references. The dated items are from 2026. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 195 candidate agents are logged for ME/CFS, most of them preliminary; this page isolates the record for one of them.

Evidence table

Evidence tierB · Moderate
Evidence score29.0 (trials 7.0, literature 12.0, tier 10, approved bonus 0.0)
Registered trials2 total: 1 recruiting, 1 active / not yet recruiting, 0 completed, 0 other
Linked publications8 (8 curated references)
Agent typeBehavioural (Behavioral / Protocol / Exercise, Drug (Pharmaceutical))
Development stage (any indication)Investigational
Mechanism / classImmunomodulatory; Neurological / Autonomic
Data sourcesOSMF therapeutic agent database, ClinicalTrials.gov, PubMed
Also known asLow-Dose Naltrexone (LDN)
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT07285473Low-Dose Naltrexone For ME/CFS: Dose-Finding
University of Alabama at Birmingham · 2026
not yet recruitingPhase 275
NCT06366724LIFT: Life Improvement Trial
Brigham and Women's Hospital · 2024
recruitingPhase 2160

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

Recorded mechanism or class: Immunomodulatory; Neurological / Autonomic.

Clinical notes: Investigational for listed conditions. 2 associated trial(s) and 5 study reference(s) in current data. Review primary sources and consult specialists before use.

Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.

Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.

Frequently asked questions

Is Low-Dose Naltrexone (LDN) approved for ME/CFS?

Low-Dose Naltrexone (LDN) is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Low-Dose Naltrexone (LDN) in clinical trials for ME/CFS?

ClinicalTrials.gov lists 2 registered trials linking Low-Dose Naltrexone (LDN) to ME/CFS: 1 is currently recruiting; 1 is active or not yet recruiting. The most advanced is Phase 2 (NCT06366724, sponsored by Brigham and Women's Hospital). It plans or enrolled 160 participants. Registration activity spans 2024 to 2026.

What does the evidence show for Low-Dose Naltrexone (LDN) in ME/CFS?

Trials of Low-Dose Naltrexone (LDN) in ME/CFS are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is B (Moderate), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.

Cite this page

Open Source Medicine Foundation. Low-Dose Naltrexone (LDN) for ME/CFS: evidence, trials and status. OSMF Research Tracker. Updated 2026-11-22. https://research.opensourcemed.info/pairs/me-cfs/low-dose-naltrexone-ldn.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-11-22. Page built 2026-11-22.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.